Imaging tumour hypoxia with Positron Emission Tomography by Fleming, I N et al.
Imaging tumour hypoxia with positron
emission tomography
I N Fleming1, R Manavaki2, P J Blower3, C West4, K J Williams5,6, A L Harris7, J Domarkas8, S Lord7, C Baldry3
and F J Gilbert*,2,6
1Aberdeen Biomedical Imaging Centre, Lilian Sutton Building, Foresterhill, Aberdeen AB25 2ZD, UK; 2Department of Radiology,
School of Clinical Medicine, University of Cambridge, Box 218-Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK;
3Division of Imaging Sciences and Biomedical Engineering, St Thomas’ Hospital, King’s College London, 4th Floor, Lambeth
Wing, London SE1 7EH, UK; 4Manchester Academic Health Science Centre, Institute of Cancer Sciences, University of Manchester,
Wilmslow Road, Manchester M20 4BX, UK; 5Manchester Pharmacy School, Faculty of Medical and Human Sciences, University
Manchester, Stopford Building, Oxford Road, Manchester M13 9PT, UK; 6EPSRC and CRUK Cancer Imaging Centre in Cambridge
and Manchester, Cambridge, UK; 7Molecular Oncology Laboratories, University Department of Medical Oncology, The
Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK
and 8Centre for Cardiovascular and Metabolic Research, Respiratory Medicine, Hull-York Medical School, University of Hull, Hull
HU16 5JQ, UK
Hypoxia, a hallmark of most solid tumours, is a negative prognostic factor due to its association with an aggressive tumour
phenotype and therapeutic resistance. Given its prominent role in oncology, accurate detection of hypoxia is important, as it
impacts on prognosis and could influence treatment planning. A variety of approaches have been explored over the years for
detecting and monitoring changes in hypoxia in tumours, including biological markers and noninvasive imaging techniques.
Positron emission tomography (PET) is the preferred method for imaging tumour hypoxia due to its high specificity and sensitivity
to probe physiological processes in vivo, as well as the ability to provide information about intracellular oxygenation levels. This
review provides an overview of imaging hypoxia with PET, with an emphasis on the advantages and limitations of the currently
available hypoxia radiotracers.
Low oxygen concentration (hypoxia) is associated with many
human pathological processes, including ischaemic heart disease,
stroke and cancer. In oncology, hypoxic tumours are associated
with a poor prognosis, an aggressive phenotype, increased risk of
invasion and metastasis, and resistance to chemo and radiation
therapy. A practical, robust and reproducible method of detecting
and quantifying hypoxia could improve patient outcomes by
allowing selection of more appropriate therapies to overcome the
effects of hypoxia or allowing stratification of patients for more
accurate prognostic information.
Tumour hypoxia has been studied with various techniques:
oxygen electrodes; extrinsic (e.g., pimonidazole) and intrinsic (e.g.,
carbonic anhydrase IX, CAIX) biomarkers; blood oxygen level-
dependent (BOLD) and tissue oxygen level-dependent (TOLD)
magnetic resonance imaging (MRI); single photon emission
computed tomography (SPECT) and positron emission tomo-
graphy (PET). Each technique interrogates different aspects of the
hypoxic microenvironment, as they provide information on
hypoxia at different locations: PET, SPECT and extrinsic markers,
report on intracellular hypoxia (although not specifically inside cell
nuclei and PET/SPECT images quantify data on a macroscopic
scale in tumour regions), BOLD-MRI allows assessment of blood
oxygenation using deoxy-haemoglobin as an endogenous marker,
while oxygen electrodes, OxyLite sampling and electron para-
magnetic resonance (EPR) predominantly measure interstitial
hypoxia. Indirect methods that report on hypoxia-induced
molecular events (e.g., GLUT1, CAIX expression) rather than
hypoxia itself have also been employed as markers of tumour
oxygenation. Positron emission tomography displays some advan-
tages for studying hypoxia, as it can employ radiotracer probes that
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directly report on oxygen levels, in principle permitting the non-
invasive and three-dimensional assessment of intratumour oxygen
levels in a more direct manner, and not via hypoxia-mediated
changes in phenotype.
Due to the clinical significance of hypoxia imaging, an
increasing number of hypoxia PET tracers are being evaluated in
the clinic. This review provides a summary and discussion of
tumour hypoxia imaging with PET, emphasising the attributes and
limitations of the currently available hypoxia radiotracers.
THE SIGNIFICANCE OF TUMOUR HYPOXIA
Tissue hypoxia is the result of inadequate tissue oxygenation due to
an imbalance between oxygen supply and consumption. Hypoxia
in solid tumours is largely due to the decreased delivery of
oxygenated blood to meet the increased metabolic demands of the
rapidly proliferating tumour cells. Other pathogenetic factors pre-
eminent in the aetiology of tumour hypoxia lie in the chaotic and
primitive tumour microvasculature, which exhibits severe struc-
tural and functional abnormalities, heterogeneous microcirculation
patterns, and an adverse geometry that poses limitations to oxygen
diffusion. In addition, the reduced oxygen binding ability and/or
transport capacity of haemoglobin, due to rouleaux formation, and
the presence of disease- or therapy-related anaemia may also
exacerbate hypoxia (Vaupel and Harrison, 2004).
Tumour hypoxia may be broadly classified as chronic and acute.
Chronic or diffusion-limited hypoxia primarily arises as a
consequence of the disorganised vascular architecture of tumours,
where the distances between tumour microvessels are often
increased from normal. Consequently, the diffusion distances of
oxygen in perivascular space—typically 70–180 mm from the
nearest capillary—are often exceeded. In addition, an adverse
vascular geometry and prolonged reductions in blood oxygen
content due to anaemia can also result in chronic hypoxia. By
contrast, acute or perfusion-limited hypoxia is characterised by
fluctuations in tumour blood flow that are caused by transient
reductions in perfusion. Both chronic and acute hypoxia can
concur in tumours, leading to the formation of a highly dynamic
microenvironment, where cells are exposed to differential oxygen
gradients both spatially and temporally (Vaupel and Harrison,
2004). Owing to the dynamic and heterogeneous character of
tumour hypoxia, imaging with PET presents an attractive
alternative, as it does not require invasive biopsies, provides
information across the entire tumour, and allows repeated and
quantifiable measurements.
Hypoxia has been shown to change gene expression to favour
survival in a hostile environment (Bristow and Hill, 2008). The
cellular response to hypoxia is mainly controlled by the family of
hypoxia-inducible factors (HIFs), and may involve regulation of up
to 1.5% of the human genome. HIF-1—the best characterised
member of the HIF family—is a heterodimeric protein, consisting
of an oxygen responsive a-subunit and a constitutively expressed
b-subunit. In the presence of oxygen, HIF-1a is continuously
synthesised and degraded, but under hypoxic conditions, the
protein accumulates, heterodimerises, and acts as a transcription
factor to upregulate a multitude of genes, including those involved
in glucose metabolism, pH regulation, apoptosis, cell survival
under oxidative stress, angiogenesis, and erythropoiesis (Semenza,
2004). These characteristics eventually confer tumours with
resistance to chemoradiation therapy and higher degrees of
invasiveness. Furthermore, hypoxia itself reduces free radical
formation induced by radiation, providing a physical contribution
to resistance. Several retrospective immunohistochemical studies
have demonstrated that hypoxia-mediated expression of HIF-1a
and its downstream genes (e.g., glucose transporter 1, GLUT-1;
vascular endothelial factor, VEGF; CAIX) is a negative prognostic
indicator for many cancer types (Jubb et al, 2010). Treatment
resistance to radio and chemotherapy has also been demonstrated.
Radiotherapy relies on the formation of free radicals that cause
DNA damage; a mechanism that is enhanced in the presence of
oxygen. Chemotherapeutic resistance may also be explained by a
multitude of mechanisms, including extracellular acidification,
resistance to apoptosis, and increased genomic instability. Conse-
quently, patients with hypoxic tumours often have a poor
prognosis and decreased overall survival rate.
MEASURING TUMOUR HYPOXIA WITH PET
Radionuclide detection of hypoxia in tumours was first reported in
1981 with 14C-misonidazole autoradiography (Chapman, 1979).
Subsequently, two main tracer classes have been developed to
specifically study hypoxia with PET: 18F-labelled nitroimidazoles
and Cu-labelled diacetyl-bis(N4-methylthiosemicarbazone) analogues
(Figure 1).
From a PET imaging perspective, hypoxia markers need to
exhibit a number of different properties. The tracer must readily
and non-specifically enter cells, sample the intracellular milieu, and
leave cells only in the presence of relevant oxygen concentrations.
A summary of the attributes of the ideal hypoxia tracer is presented
in Table 1. Most PET tracers tested clinically broadly display
attributes 1, 4, 5, and 7. The clinical utility of each tracer depends
on these key properties, which will influence its distribution in
tissues, clearance rate from blood, normoxic and hypoxic cells,
metabolism, optimal image acquisition time and ease of synthesis,
distribution.
NITROIMIDAZOLE ANALOGUES
2-Nitroimidazole compounds were originally developed as hypoxic
cell radiosensitisers and were introduced as hypoxia markers in the
1970s (Chapman, 1979). Nitroimidazoles enter cells by passive
diffusion, where they undergo reduction forming a reactive
intermediate species. Under normoxic conditions, these molecules
are re-oxidised into their parent compound and diffuse out of the
cell. However, hypoxia causes further reduction of the nitro-radical
anion, which eventually becomes irreversibly trapped in the cell at
rates that are inversely proportional to the local pO2. As reduction
of nitroimidazoles requires the presence of active tissue reductases,
these compounds accumulate within viable hypoxic cells, but not
apoptotic or necrotic cells.
18F-fluoromisonidazole. Over the years, several fluorinated
nitroimidazole-based markers have been developed for PET
imaging. Of these, 18F-fluoromisonidazole (18F-FMISO) constitutes
the prototype 2-nitroimidazole tracer, and is the most extensively
clinically studied PET hypoxia biomarker. The lipophilic nature of
this compound ensures facile cell-membrane penetration and
diffusion into tissue, and several studies correlating direct oxygen
measurements with 18F-FMISO accumulation in vivo demonstrate
that a median oxygen level ofp10mmHg is generally required for
hypoxia-specific retention. The 18F-FMISO accumulation has been
found to reflect hypoxia in gliomas (Valk et al, l992; Bruehlmeier
et al, 2004; Rajendran et al, 2004; Cher et al, 2006; Swanson et al,
2009), head-and-neck (Rasey et al, 1996; Gagel et al, 2004, 2007;
Hicks et al, 2005; Thorwarth et al, 2006; Zimny et al, 2006;
Mortensen et al, 2010; Abolmaali et al, 2011; Sato et al, 2013),
breast (Cheng et al, 2013), lung (Cherk et al, 2006; Vera et al,
2011), and renal tumours (Hugonet et al, 2011). However, 18F-
FMISO retention in sarcomas is variable (Rajendran et al, 2003;
Mortensen et al, 2010), rectal 18F-FMISO imaging is compromised
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by high non-specific tracer accumulation in normoxic tissue (Roels
et al, 2008) whereas no retention was observed in pancreatic
tumours (Segard et al, 2013). Several clinical studies have shown
that a tumour-to-blood activity ratio of X1.2 imaged after at least
2 h post injection (p.i.) can be generally considered as indicative
of hypoxia (Table 2). Although not commercially available, 18F-
FMISO is produced by a number of institutions, making it
available for research purposes.
Due to its hypoxic selectivity, 18F-FMISO is the lead candidate
in the assessment of hypoxia with PET. However, despite its wide
applicability, 18F-FMISO has not gained general acceptance for
routine clinical use due to its slow pharmacokinetic profile: the
limited clearance of the tracer from normal tissue and blood results
in modest hypoxic-to-normoxic tissue ratios (Figure 2) and
therefore images with moderate contrast (Figure 3A). The limited
hypoxic contrast may potentially impede visual detection of
hypoxic regions, and has hampered diagnostic utility in routine
practice. Therefore, considerable efforts have been made to develop
hypoxia markers with improved pharmacokinetic properties
(enhanced clearance of the tracer from normoxic tissues) that
are more amenable to clinical use. These are discussed below.
18F-fluoroazomycin-arabinofuranoside. 18F-fluoroazomycin-ara-
binofuranoside (18F-FAZA) is more hydrophilic than 18F-FMISO.
Consequently, there are faster clearance kinetics, resulting in
improved tumour-to-reference tissue ratios, and thus hypo-
xia-to-normoxia contrast. The 18F-FAZA imaging has been
successful in gliomas (Postema et al, 2009), lymphomas
(Postema et al, 2009), lung (Postema et al, 2009; Bollineni
et al, 2013; Trinkaus et al, 2013), head-and-neck (Grosu et al,
2007; Souvatzoglou et al, 2007; Postema et al, 2009; Mortensen
et al 2012), cervical (Schuetz et al, 2010), and rectal tumours
(Havelund et al, 2013), and results have been shown to compare
favourably with equivalent 18F-FMISO data, especially as
improved hypoxic-normoxic contrast was obtained at earlier
time points. No 18F-FAZA accumulation has been observed in
prostate tumours, although hypoxia may not be a characteristic
of this particular tumour type, as in the same study, CAIX
immunohistochemistry was also found to be negative in these
lesions (Garcia-Parra et al, 2011). High 18F-FAZA tumour-to-
reference tissue values have been associated with reduced
disease-free survival and have shown prognostic potential in
the detection of hypoxia in head-and-neck patients (Mortensen
et al, 2012). Due to the higher tumour-to-reference tissue ratios
in comparison with 18F-FMISO, 18F-FAZA is gaining popularity
for PET imaging of tumour hypoxia. Despite the fact that 18F-
FAZA is not widely available at present, increasing research
demand may persuade more sites to produce it.
Table 1. Characteristics of the ideal hypoxia tracer
1 Hypoxia-specific retained in regions with low pO2 levels, but not by normoxic or necrotic cells
2 Mechanism of cellular retention should be well defined and cell type independent
3 Sufficiently lipophilic to enter cells and allow uniform tissue distribution, but also sufficiently hydrophilic to avoid membrane sequestration, and have faster
clearance from systemic circulation and normoxic tissue
4 Pharmacokinetic profile and tissue distribution should exhibit little dependence on parameters that may co-vary with hypoxia, such as blood flow or pH
5 High stability against non-hypoxia specific metabolism in vivo
6 Tissue kinetics should be suitable to imaging within a timeframe permitted in the clinical setting
7 Should be easy to synthesise and readily available
8 Amenable dosimetry profile
9 Be repeatable to allow both detection of hypoxia and return to normoxia
10 Should be effective in multiple tumour types
pO2: partial oxygen pressure (mmHg).
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Figure 1. Structures and logP-values of PET hypoxia radiotracers. The logP-value (partition coefficient) of each radiotracer is shown in the
parentheses. Positive logP-values indicate a lipophilic molecule, whereas negative logP-values represent a hydrophilic molecule.
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Table 2. Clinical hypoxia studies with PET in tumours
Reference Tracer
Tumour
type(s)
N Tracer retention (TBR; SUV) Results
Valk et al (1992) 18F-FMISO Brain 3 T:P: 0.71–1.49 at 120min p.i. 18F-FMISO-PET is a feasible method for detecting
hypoxia in gliomas
Bruehlmyer et al (2004) 18F-FMISO Brain 11 T:B: 0.96–2.07 at 90min and
X170min p.i.
Increased 18F-FMISO T:B observed in all tumours. T:B
independent of tumour perfusion at later imaging times
Cher et al (2006) 18F-FMISO Brain 17
Static scan at 120min p.i.
18F-FMISO uptake in high-grade, but not in low-grade,
gliomas. Correlation between 18F-FDG or 18F-FMISO
uptake with Ki67 and VEGFR-1 expression
Swanson et al (2009) 18F-FMISO Brain 24 T:Bmax,pre-therapy:2.7
T:Bmax,post-therapy:1.7
Hypoxia volume generally straddled outer edge of the
T1-Gd abnormality. Correlation between hypoxic
volume and T1-Gd abnormality.18F-FMISO T:B reduced
after therapy
Cheng et al (2013) 18F-FMISO Breast 20 T:M2h,Baseline: 0.72–3.07
T:M4h,Baseline: 0.8–2.29 (16/20
patients)
T:M2h,Follow-up: 0.27–1.83
T:M4h,Follow-up: 0.43–2.28 at 120min
and 180min p.i.
Hypoxia thresholds: T:M41.2;
SUVX2.1
Correlation between FMISO uptake and endocrine
therapy outcome. Poor correlation between FMISO
uptake and HIF-1a immunostaining
Gagel et al (2004) 18F-FMISO H&N 16 T:M: 1.68 (range, 1.23–2.28)
Av SUVmean: 1.76; Av. SUVmax: 2.07
at 120min p.i.
Average to high correlation between oxygen electrode
and 18F-FMISO T:M and SUV. No correlation between
tumour oxygenation status and 18F-FDG uptake
Hicks et al (2005) 18F-FMISO H&N 15 SUVmax
Tumour: 2.5±0.5
Nodes: 2.3±0.5 at 120min p.i.
Positive 18F-FMISO uptake in 13 patients. Qualitative
decrease in 18F-FMISO and 18F-FDG uptake induced by
therapy
Thorwarth et al (2005) 18F-FMISO H&N 15 Median SUVmax: 2.25 (range, 1.36–
4.04) at 120min and 180min p.i.
Different types of characteristic hypoxia-perfusion
patterns identified in tumours
Rajendran et al (2006) 18F-FMISO H&N 73 Mean T:Bmax1.6±0.46 T:B and the presence of nodes were strong independent
predictors of survival
Rischin et al (2006) 18F-FMISO H&N 45 Independent hypoxic score
Static scan at 120min p.i.
Higher risk of locoregional failure in hypoxic tumours.
Patients on tirapazamine had lower risk of locoregional
failure
Thorwarth et al (2006) 18F-FMISO H&N 12 SUVmax: 2.20 (range, 1.4–3.22) at
120min and 240min p.i
Hypoxia definition: SUV41 4
No correlation between 18F-FDG and 18F-FMISO SUV.
Maximum 18F-FMISO SUV showed borderline
significance for stratifying patient group
Zimny et al (2006) 18F-FMISO H&N 24 Normoxic T:Mmean1.4
Hypoxic T:Mmean: 1.8
18F-FMISO T:M higher in hypoxic tumours (as detected
with oxygen electrode). Moderate correlation between
18F-FDG and 18F-FMISO uptake
Eschmann et al (2007) 18F-FMISO H&N 14 SUVmean, pre-therapy 2.54±0.81
T:M pre-therapy 1.9±0.64
SUVmean, post-therapy: 1.98±0.47, T:M
post-therapy: 1.49±0.26 at 240min p.i.
Hypoxia definition: T:MX2
threshold
Radiotherapy decreased18F-FMISO SUV and T:M ratio
Gagel et al (2007) 18F-FMISO H&N 38 SUVmean: 1.69
SUVmax: 1.98
T:Mmean: 1.57
T:Bmean: 1.13
Moderate correlation between oxygen measurements
and 18F-FMISO uptake. Low correlation between
18F-FDG and 18F-FMISO
Lee et al (2008) 18F-FMISO H&N 20 Static scan at 120–150min p.i.
Hypoxia definition: T:MX1.3
Variable 18F-FMISO distribution
Nehmeh et al (2008) 18F-FMISO H&N 13 SUV 1.9–4.5 at 117–195 p.i.
TBRX1.2
Good correlations intratumour18F-FMISO distributions in
6/13 patients, consistent with chronic hypoxia
Dirix et al (2009) 18F-FMISO H&N 15 Hypoxic volumepre-therapy 4.1ml,
T:Bmax, pre-therapy: 1.5
Hypoxic volume post-therapy: 0.3ml
T:Bmax,post-therapy: 1.2 at 120–
160min p.i
Hypoxia definition: T:B41.2
Disease-free survival correlates negatively with baseline
T:Bmax and initial hypoxic volume
Lee et al (2009) 18F-FMISO H&N 28 — Heterogeneous distribution of 18F-FMISO noted in the
primary and/or nodal disease in 90% of patients
Abolmaali et al (2011) 18F-FMISO H&N 23 SUVmax,2h: 2.2 (range, 1.3–3.4)
T:M2h: 1.46
SUVmax,4h: 2.4 (range,1.1–4.4)
T:M4h: 1.6
18F-FMISO contrast increases 2–4 h p.i.
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Table 2. ( Continued )
Reference Tracer
Tumour
type(s)
N Tracer retention (TBR; SUV) Results
Kikuchi et al (2011) 18F-FMISO H&N 17 Median SUVmax: 2.3
Median T:M: 1.3 at 150min p.i.
Hypoxia definition: 1.3
Disease-specific survival was significantly lower in
patient group with high basal 18F-FMISO SUVmax and
T:Mmax
Yamane et al (2011) 18F-FMISO H&N 13 SUVmax,pre-therapy2.2 (range,
0.7–3.6)
T:M,pre-therapy: 1.6 (range: 1.1–2.2).
Responders: –18.7% SUVmax;
–22.5% T:M; –82.65% hypoxic
volume non-responders: –5.5%
SUVmax
10.2% T:M
–8.8% hypoxic volume (–/þ denote
% increase and decrease,
respectively) at 150min p.i.
18F-FMISO SUVmax, T:M and hypoxic volume
significantly decreased after neo-adjuvant
chemotherapy
Sato et al (2013) 18F-FMISO H&N 23 Median SUVmax: 1.83 (range,
0.8–2.7)
Median SUVmax: 16.5 (range,
1.0–32.3)
Weak significant correlation between 18F-FMISO and
18F-FDG SUVmax.
18F-FMISO SUVmax was significantly
higher in HIF-1a-positive cases than in HIF-1a-negative
cases
Okamoto et al (2013) 18F-FMISO H&N 11 SUVmax,Baseline: 3.16±1.29
SUVmax,48h: 3.02±1.12
T:BBaseline: 2.98±0.83
T:B48h: 2.97±0.64
T:MBaseline: 2.25±0.71
T:M48h: 2.19±0.67 at 240min p.i.
Hypoxia threshold: T:BX1.5;
T:MX1.25
High reproducibility between SUV, T:B, T:M and hypoxic
volume measurements between the two 18F-FMISO
scans (baseline and at 48 h)
Mortensen et al (2010) 18F-FMISO H&N
Sarcoma
19 T:Mmed: H&N: 1.68 (range,
0.7–2.38)
Sarcoma: 0.78 (range, 0.7–1)
No correlation between 18F-FMISO retention and
oxygen electrode
Koh et al (1995) 18F-FMISO Lung 7 Static scan at 120–180 p.i.
TBRX1.4 threshold to define
hypoxia
Radiotherapy reduced median fractional hypoxic volume
from 58 to 22%
Cherk et al (2006) 18F-FMISO Lung 21 SUV: 0.4–2.14; T:N: 1.18–9.73 at
120min p.i.
Low 18F-FMISO uptake. Poor correlation between
18F-FMISO and 18F-FDG uptake
Gagel et al (2006) 18F-FMISO Lung 8 SUVmean, pre-therapy: 2.31±0.2
SUVmax, pre-therapy: 2.77 ±0.27
T:Mpre-therapy: 1.99±0.49
SUVmean, post-therapy: 1.83±0.12
SUVmax, post-therapy: 2.19±0.13
T:Mpost-therapy: 1.36±0.08 at
180min p.i.
18F-FMISO can define hypoxic sub-regions. Changes in
FMISO and 18F-FDG PET measure early response to
therapy
Vera et al (2011) 18F-FMISO Lung 5 SUVmax, pre-therapy: 1–2.5
SUVmax, post-therapy: 1–2.4
18F-FMISO uptake higher in tumours than in nodes and
did not change during therapy
Thureau et al (2013) 18F-FMISO Lung 10 — Low reproducibility and inter-observer agreement for
18F-FMISO volume measurements on the basis of visual
scoring. T:MX1.4 recommended for hypoxic volume
delineation
Segard et al (2013) 18F-FMISO Pancreatic 10 Mean SUVmax: 2.3 (range, 1–3.4)
18F-FMISO accumulation observed in 2/10 patients on
the basis of visual analysis. Minimal 18F-FMISO
accumulation in pancreatic tumours; correlation with
other imaging modalities required to allow tumour
localisation and semi-quantitative analysis
Hugonet et al (2011) 18F-FMISO Renal 53 Static scan at 120min p.i.
Hypoxia definition: TBR41.2
Reduction in hypoxic volume post-therapy
Roels et al (2008) 18F-FMISO Rectal 15 Mismatch between 18F-FDG and 18F-FMISO scans.18F-
FMISO uptake reduced after therapy
Bentzen et al (2003) 18F-FMISO Sarcoma 13 T:M o1–1.6 18F-FMISO accumulation observed in 2/7 malignant
tumours.
No correlation between 18F-FMISO and pO2
measurements
Rajendran et al (2003) 18F-FMISO Sarcoma 19 T:Bmax 1.10–3.46 at 120min p.i.
TBRX1.2 to define hypoxia
18F-FMISO uptake observed in 14 patients. Poor
correlation between tumour grade, hypoxia volume and
18F-FDG T:B
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Table 2. ( Continued )
Reference Tracer
Tumour
type(s)
N Tracer retention (TBR; SUV) Results
Rajendran et al (2004) 18F-FMISO Brain
Breast
H&N
Sarcoma
49 T:Bmax: Brain 2.43 (range, 1.7–2.9)
Breast 1.52 (range, 0.93–2.6)
H&N: 1.5 (range, 0.88–2.4)
Sarcoma: 1.46 (range, 1.1–2.1)
Hypoxia detected in all tumour types. Low correlation
between glucose metabolism and hypoxia
Schuetz et al (2010) 18F-FAZA Cervical 15 T:Mmax: 1.2–3.6 at 60min and
120min p.i.
5/15 patients had visually identifiable tumours.
Grosu et al (2007) 18F-FAZA H&N 18 T:Mmean: 1.6
T:Mmax: 2 at 120min p.i.
Hypoxia threshold: SUVX1.5
18F-FAZA uptake located in single confluent region in
11/18 patients and as multiple diffuse regions in 4/18
patients
Souvatzoglou et al
(2007)
18F-FAZA H&N 11 SUVmax: 2.3 (range, 1.5–3.4)
SUVmean: 1.4 (range, 1–2.1)
T:M: 2 (range, 1.6–2.4)
T:M ratio increased 60min p.i. All tumours had
T:M41.5  Tumour volume with T:M41.5 was highly
variable
Mortensen et al (2012) 18F-FAZA H&N 40 Median T:Mmax1.5 at 120min p.i.
Hypoxia threshold: X1.4
High uptake associated with lower disease-free survival.
Radiotherapy treatment reduced hypoxic volume
Bollineni et al (2013) 18F-FAZA Lung 11 Median T:B: 2.8 (range, 1.8–4.6)
T:BX1.2 for hypoxic volume
definition
Not significant correlation between 18F-FAZA T:B and
18F-FDG SUVmax or lesion size. Heterogeneous
intratumoural distribution for 18F-FAZA-based visual
analysis.18F-FAZA PET is able to detect heterogeneous
distributions of hypoxic sub-volumes
Trinkhaus et al (2013) 18F-FAZA Lung 17 — 11/17 patients had baseline hypoxia based on
qualitative assessment. 6/8 patients with scans following
chemoradiation had resolution of hypoxia on the basis of
qualitative analysis
Garcia-Parra et al
(2011)
18F-FAZA Prostate 14 T:Nmean: 1.21
18F-FAZA uptake not increased in tumours. No evidence
of hypoxia as assessed by CaIX IHC staining
Havelund et al (2013) 18F-FAZA Rectal 14 T:Mmean: 2.83
18F-FAZA-PET is feasible for visualisation of hypoxia in
rectal cancer
Postema et al (2009) 18F-FAZA H&N
Lung
Lymphoma
Glioma
50 H&N TBR: 1.2–2.7;
SUVmax1.05–2.35
Lung TBR: 1.3–3.7;
SUVmax0.81–1.93
Lymphoma TBR: 1.2–3; SUVmax1.07–
4.52
Glioma TBR: 1.9–15.6 At
120–180min p.i.
High TBR in all 7 gliomas; high TBR, SUVmax observed in
6/9 H&N tumours; moderate TBR, SUVmax in 3/21
lymphomas; increased TBR, SUVmax in 7/11 lung patients
Lehtio¨ et al (2001) 18F-FETNIM H&N 8 T:Mmax 1–4 at 3 h p.i. Tumour distribution volume correlated strongly with
18F-
FETNIM SUV between 60 and 120min p.i. and blood
flow, but not with 18F-FDG SUV. Values compare
favourably with 18F-FMISO data. Late time-point 18F-
FETNIM T:M are indicative of hypoxia
Lehtio¨ et al (2003) 18F-FETNIM H&N 10 Median T:M: 1.41 (range, 0.86–2)
Median T:Pmean: 0.96
(range, 0.74–1.1)
Median T:Pmax: 1.29
(range, 0.91–1.98)
T:P is good estimate of tumour hypoxia
Lehtio¨ et al (2004) 18F-FETNIM H&N 21 Median T:Pmax: 1.10
(range, 0.81–1.98)
T:P40.93 used for hypoxic volume
definition
Patients with higher fractional hypoxic volumes and T:P
correlated with poorer survival
Hu et al (2013) 18F-FETNIM Lung 42 SUVmax,Tumour: 2.43
SUVmax,Normal: 0.87
T:N: 2.48 at 120min p.i.
SUVmax higher in tumours than in normal tissue. Similar
data observed at 60 and 120min p.i.
Li et al (2010) 18F-FETNIM Lung 26 – 18F-FETNIM T:B ratio and hypoxic volume were strong
predictors for overall survival. No correlation between
18F-FETNIM and18F-FDG uptake
Vercellino et al (2012) 18F-FETNIM Cervical 16 T:M: 1.3–5.4 High uptake associated with lower progression free and
overall survival
Yue et al (2012) 18F-FETNIM Oesophageal 28 SUVmax, complete response: 3.2
SUVmean, complete response: 2.1
SUVmax, partial response: 4.5
SUVmean, partial response: 2.9
SUVmax, stable disease: 5.9
SUVmean, stable disease: 3.2
Threshold for hypoxia
SUVmax:SUVmean,spleen: 1.3
SUVmax and SUVmean are reproducible. High baseline
SUVmax associated with poor clinical response
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18F-fluoroerythronitroimidazole. 18F-fluoroerythronitroimidazole
(18F-FETNIM) studies in head-and-neck (Lehtio¨ et al, 2001, 2003),
lung (Li et al, 2010; Hu et al, 2013), and oesophageal cancer Yue
et al (2012) calculated T:M in the range of 1.4–2.48 at 2 h p.i. High
tumour-to-muscle values were found to be indicative of reduced
progression-free and overall survival in lung (Li et al, 2010; Hu
et al, 2013), head-and-neck (Lehtio¨ et al, 2004), oesophageal (Yue
et al, 2012), and cervical (Vercellino et al, 2012) tumours. Clinical
studies with 18F-FETNIM have been mainly carried out at the
University of Turku, Finland. 18F-fluoroerythronitroimidazole
is not being used at present in the United Kingdom or in the
United States.
18F-RP-170. More recently, RP-170 (1-(2-1-(1H-methyl)ethoxy)-
methyl-2-nitroimidazole), another 2-nitroimidazole-based hypoxic
radiosensitiser, has also been labelled with 18F. The hypoxic
selectivity of 18F-FRP-170 was demonstrated in glioma patients on
the basis of significant correlations between uptake, oxygen tension
measurements and HIF-1a immunostaining (Beppu et al, 2014).
Studies in brain (Shibahara et al, 2010; Beppu et al, 2014) and lung
(Kaneta et al, 2007) tumours indicated higher SUV for hypoxic
than normal tissues; tumour-to-reference tissue ratio of 1.7 was
calculated at 1 h p.i., which could be clinically sufficient for
assessing hypoxia. The shorter interval before scanning, combined
with improved hypoxic contrast compared with 18F-FMISO,
suggests that 18F-FRP-170 could potentially be useful in the clinic.
18F-HX4. 18F-3-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-
1H-1,2,3-triazol-1-yl)propan-1-ol (18F-HX4) contains a 1,2,3-
anti-triazole moiety (as a synthetic convenience) rendering it more
hydrophilic than 18F-FMISO. In head-and-neck tumours, 18F-HX4
produced tumour-to-reference tissue values similar to 18F-FMISO
at relatively early time points p.i., indicating the potential
advantage of shorter acquisition times (Chen et al, 2012). However,
a more recent study in non-small-cell lung cancer (NSCLC)
patients (Zegers et al, 2013) suggested that later scan times (2–4 h
Table 2. ( Continued )
Reference Tracer
Tumour
type(s)
N Tracer retention (TBR; SUV) Results
Zegers et al (2013) 18F-HX4 Lung 15 SUVmax,2h: 1.47±0.36
SUVmax,4h: 1.34±0.37
T:Bmax,2h: 1.56±0.30
T:Bmax,2h: 2.03±0.55 at 240min p.i.
Hypoxia threshold: T:B41.4
T:Bmax41.4 at 240min p.i. was observed in 80% of the
primary tumours and 60% of lymph-node regions. T:Bmax
increased over acquisition time, although pattern
stabilised between 120 and 180min p.i.
Kaneta et al (2007) 18F-FRP170 Normal lung 4/
3
T:M1h: 1.69
T:B1h: 1.09
T:M2h: 1.96
T:B2h: 1.24 at 120min p.i.
T:B stable at 60–120min p.i. Images obtained 60min p.i.
may allow evaluation of tumour accumulation in a clinical
setting
Shibahara et al (2010) 18F-FRP170 Brain 8 SUVmax: 1  3–2  3 SUVmax correlated positively with HIF–1a
immunostaining.
Beppu et al (2014) 18F-FRP170 Brain 12 SUVmean, Tumour: 1.58±0.35
SUVmean, Normal: 0.82±0.16
T:N: 1.95±0.33
Significant correlation between T:N, pO2, and strong
nuclear immunostaining for HIF-1a in areas of high 18F-
FRP-170 accumulation 60min p.i. in glioblastoma
patients
Dehdashti et al
(2003a, b)
60Cu-ATSM Cervical 14 Mean T:M: 3.4±2.8 Tumour uptake of 60Cu-ATSM inversely related to
progression-free survival and overall survival. No
correlation between FDG and 60Cu-ATSM uptake
Grigsby et al (2007) 60Cu-ATSM Cervical 15 — 4 year overall survival estimates were 75% for patients
with non-hypoxic tumours and 33% for those with
hypoxic tumours. Overexpression of VEGF, EGFR,
COX2, CAIX and increased apoptosis observed in
hypoxic tumours
Dehdashti et al (2008) 60Cu-ATSM Cervical 38 T:M 3.8±2.0 Tumour uptake of 60Cu-ATSM was inversely related to
progression-free survival and cause-specific survival.
3-year progression-free survival of patients with
non-hypoxic tumours was 71%, and 28% for those with
hypoxic tumours
Minagawa et al (2011) 62Cu-ATSM H&N 15 Mean SUVmax5.5±1.7 All 5 patients with SUVmaxo5 were complete responders
Dehdashti et al
(2003a, b)
60Cu-ATSM Lung 19 Mean T:Mpre-therapy2.3±1
Mean SUVmean, pre-therapy:3.2±1
Responders: Mean
T:M pre–therapy: 1.5
Non-responders: Mean
T:Mpre-therapy: 3.4
Imaging with 60Cu-ATSM feasible in NSCLC. Mean T:M
lower in responders than in non-responders. Mean SUV
not different between these groups
Dietz et al (2008) 60Cu-ATSM Rectal 19 Mean T:M 2.5±0.9 at 30–60min p.i.
Hypoxia threshold: T:M42.6
Median tumour-to-muscle activity ratio of 2.6
discriminated those with worse prognosis from those
with better prognosis. Overall and progression-free
survival worse in hypoxic tumours
Lohith et al (2009) 62Cu-ATSM Lung 13 SUVmean, SCC: 1.95±0.88
SUVmean, Adenocarcinoma: 1.54±0.92
at 30min and 60min p.i.
18F-FDG and 62Cu-ATSM had spatially similar
distributions in adenocarcinomas
Abbreviations: CAIX¼ carbonic anhydrase IX; EGFR¼ epidermal growth factor; H&N¼ head and neck cancer; N¼ number of patients; NSCLC¼ non-small cell lung cancer; pO2¼partial
oxygen pressure; p.i.¼post injection; RT¼ radiotherapy; SUV¼ standardised uptake value; ; TBR¼ tumour-to-background ratio; T:B: tumour-to-blood ratio; T:P¼ tumour-to-plasma ratio;
T:M¼ tumour-to-muscle ratio; T:N¼ tumour-to-normal tissue ratio; VEGFR¼ vascular endothelial growth factor.
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p.i.) can further enhance the hypoxic-to-normoxic signal. In all of
the above tracers, the more accurate hypoxic measure is made at
least 2 h p.i., but the trade-off is the reduced radioactivity and
noisier data.
CU-DIACETYL-BIS(N4-METHYLTHIOSEMICARBAZONE)
An alternative class of agents for the study of hypoxia with PET is
based on a complex of Cu with diacetyl-bis(N4-methylthiosemi-
carbazone) (ATSM) ligands, among which ATSM is the prototype.
Due to its lipophilicity and low molecular weight, Cu-ATSM is
characterised by high membrane permeability and therefore rapid
diffusion into cells. The hypoxic specificity of Cu-ATSM is thought
to be partly imparted by the intracellular reduction of Cu(II) to
Cu(I) combined with re-oxidation by intracellular molecular
oxygen. Under hypoxic conditions, the unstable Cu(I)–ATSM
complex may further dissociate into Cu(I) and ATSM, leading to
the intracellular trapping of the Cu(I) ion. In the presence of
oxygen, the [Cu(I)-ATSM]– can be re-oxidised to its parent
compound, allowing efflux from the cell (Dearling and Packard,
2010).
Tumour-specific Cu-ATSM retention has been demonstrated
for head-and-neck (Minagawa et al, 2011; Nyflot et al, 2012)
(Figure 3B), lung (Takahashi et al, 2000; Dehdashti et al, 2003a, b;
Lohith et al, 2009), cervical (Dehdashti et al, 2003a, b; Grigsby et al
2007; Lewis et al, 2008; Dehdashti et al, 2008), rectal tumours
(Dietz et al, 2008) and gliomas (Tateishi et al, 2013). Hypoxia
specificity may be dependent on tumour type: preclinical studies
showed good correlation in the intratumour distribution of Cu-
ATSM and 18F-FMISO in a FaDu squamous carcinoma model but
not at early time points in an R3327-AT anaplastic rat prostate
tumour (O’Donoghue et al, 2005). A recent study has raised
concerns about the hypoxic specificity of Cu-ATSM, as hepatic
metabolism of the compound results in images that reflect the
behaviour of ionic Cu (uptake of which may itself be hypoxia-
related) rather than Cu-ATSM itself, especially at later time points
(1–24 h) (Hueting et al, 2014). Of concern is also the fact that while
some preclinical studies show that tumour uptake of hypoxia-
selective Cu-ATSM analogues (e.g., Cu-ATSE) decreases with
increased oxygenation (McQuade et al, 2005), another report
showed that increased oxygenation resulted in a decrease in uptake
of FMISO, but not of Cu-ATSM (Matsumoto et al, 2007).
Nevertheless, 64Cu-ATSM retention has been shown to correlate
clinically with poor prognosis (Dehdashti et al, 2003a, b; 2008;
Grigsby et al, 2007; Dietz et al, 2008). Attempts to investigate the
relationship between the intratumoural distribution of Cu-ATSM
with histological and other hypoxia markers have also yielded both
positive and negative correlations. Although it appears to be
premature to reject Cu-ATSM on the grounds of hypoxic non-
specificity, further studies are required to elucidate the in vivo
behaviour of this tracer to allow for better interpretation of the
imaging information. The development of second-generation Cu-
ATSM analogues, with reduced lipophilicity and improved hypoxia
selectivity and sensitivity, appears to be a promising alternative to
Cu-ATSM (Handley et al, 2014). Cu-ATSM has several potential
advantages relative to other tracers for the imaging of tumour
hypoxia, including simpler synthesis/radiolabelling methodology
and faster clearance from normoxic tissues, which allows shorter
intervals between injection and imaging and higher hypoxic-to-
normoxic contrast. Notwithstanding the limited availability of Cu
isotopes, 64Cu-ATSM is currently being produced at a few research
sites, and due to the 12-h half-life could potentially be utilised for
clinical studies.
CLINICAL APPLICATIONS OF PET HYPOXIA IMAGING
Identification of tumour hypoxia and prediction of prognosis/
response to treatment. Identifying individuals with poor prog-
nosis and those likely to benefit from hypoxia-targeted therapy are
important objectives of PET hypoxia research. Several studies have
shown that PET hypoxia imaging can provide information on
prognosis. High 18F-FMISO retention has been associated with
higher risk of loco-regional failure and shorter progression-free
survival in head-and-neck (Rischin et al, 2006; Rajendran et al,
2006; Thorwarth et al, 2006; Dirix et al, 2009; Lee et al, 2009;
Kikuchi et al, 2011) and renal cancer (Hugonet et al, 2011).
Furthermore, a meta-review of the clinical data of over 300 patients
concluded that FMISO is a predictor of poor treatment response
and prognosis (Lee and Scott, 2007). Similar results have been
reported for 18F-FETNIM in lung (Li et al, 2010), head-and-neck
(Lehtio¨ et al, 2004), and oesophageal cancer (Yue et al, 2012),
where high tumour-to-reference tissue values were also associated
with poor patient outcomes. Studies conducted with 18F-FAZA in
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Figure 2. Tumour-to-reference tissue ratios and range in different
tumour sites for the PET hypoxia tracers discussed in this review.
For nitroimidazole-based analogues (FMISO, FAZA, FETNIM, HX4,
FRP-170) values are given for acquisitions performed at 120min post
tracer administration. For Cu-ATSM, values are presented for scans
conducted 60min.
Figure 3. (A) Transverse 18F-FMISO fused PET/CT overlay image
acquired at baseline of a patient with metastatic renal cell carcinoma
(mRCC) in the neck acquired at 2.5–3 h p.i (image courtesy of
Professors Tim Eisen and Duncan Jodrell, University of Cambridge,
UK). (B) 64Cu-ATSM fused PET/CT overlay image of a patient with
advanced laryngeal squamous cell carcinoma (LSCC) at 80–90min p.i.
The transverse slice includes primary tumour and local lymph
node (image courtesy of Dr Anastasia Chalkidou, King’s College
London, UK).
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squamous cell carcinomas of the head and the neck (Mortensen
et al, 2012) and Cu-ATSM in patients with cervical (Dehdashti
et al, 2003a, b; Grigsby et al, 2007), lung (Dehdashti et al, 2003a, b),
and rectal cancer (Dietz et al, 2008) have also demonstrated that
lower tumour-to-muscle ratios are indicative of better prognosis,
progression-free and overall survival. A meta-analysis of published
PET hypoxia studies has demonstrated a common tendency
towards poorer outcome in tumours showing higher tracer
accumulation (Horsman et al, 2012). Decreased 18F-FMISO uptake
in response to radio- or chemotherapy has been reported in brain
(Swanson et al, 2009), head-and-neck (Yamane et al, 2011;
Eschmann et al, 2007), lung (Koh et al, 1995; Gagel et al, 2006),
and renal tumours (Hugonet et al, 2011); although some studies
did not observe an analogous decrease with response to therapy
(Thorwarth et al, 2006; Vera et al, 2011). Decreased tumour-to-
muscle ratios signifying full or partial response to chemotherapy
have also been obtained with Cu-ATSM in lung (Dehdashti et al,
2003a, b) and head-and-neck tumours (Minagawa et al, 2011), and
18F-FAZA in lung cancer (Trinkaus et al, 2013).
RADIOTHERAPY PLANNING
In oncology, there is interest in the identification of intratumoural
areas with hypoxia to guide radiation dose escalation to radio-
resistant sub-volumes. Despite possible limitations associated with
the reproducibility of hypoxic volume measurements (temporal
changes and/or heterogeneity in the spatial distribution of
intratumoural hypoxia), the biological information from PET
hypoxia scans is being explored for the identification and
delineation of hypoxic areas within the tumour mass for dose
escalation. Modern radiation techniques, such as intensity
modulated radiotherapy (IMRT) or image-guided radiotherapy
(IGRT) can help with radiotherapy planning (Horsmann et al,
2012). ‘Dose painting’ by numbers, where a higher radiation dose is
selectively delivered to areas of biological resistance identified
either before or during the treatment course, has also been
suggested (Geets et al, 2013). The feasibility of dose escalation to
hypoxic sub-volumes has been primarily investigated in cancers of
the head and neck, lung, and brain, and demonstrated with
Cu-ATSM (Chao et al, 2001), 18F-FMISO (Lee et al, 2008), and
18F-FAZA (Grosu et al, 2007). Despite the fact that the majority
of the aforementioned studies have not been conducted on
actual patients, but on anthropomorphic phantoms (in silico)
(Rischin et al, 2006; Grosu et al, 2007; Lee et al, 2008), dose
escalation on the basis of PET hypoxia imaging appears to be
feasible, and further studies are required to investigate whether this
can translate into clinical benefit.
HYPOXIA THERAPEUTICS
As the hypoxic microenvironment constitutes a unique character-
istic of tumours, hypoxia can also be harnessed as a therapeutic
target. The main strategies for targeting hypoxia involve hypoxic
cell radiosensitisers (e.g., nimorazole), hypoxic cell cytotoxins (e.g.,
tirapazamine, TH-302, and PR-104A); and altering oxygen delivery
(e.g., carbogen plus nicotinamide). Other approaches being
investigated include hypoxia-selective gene therapy, altering
metabolic pathways essential for survival under stress, and
inhibitors of molecular targets activated in hypoxia (e.g., HIF-1)
(Wilson and Hay, 2011). Imaging hypoxia with PET could facilitate
the development of therapeutic agents by identifying patients with
hypoxic tumours, and measuring response to hypoxia-modifying
treatments providing a basis for individualising hypoxia-specific
treatment, and/or assessing drug efficacy. Furthermore, it will allow
development of new predictors and answer key questions, such as
the relation of baseline or induced hypoxia to response to anti-
angiogenic drugs and the relation of baseline hypoxia to response
to hypoxic-activated toxins. Such studies should be incorporated
into trials of these agents routinely, to develop the necessary
validation for their utility. This would greatly help the personalised
and economic use of such therapies, which will be even more
important if used in combination, for example, anti-angiogenics
and hypoxia-activated toxins. The potential of PET hypoxia
imaging in directing hypoxia therapeutics has been clinically
demonstrated with tirapazamine with 18F-FMISO in head and neck
tumours, whereby only those with hypoxia benefited from
bioreductive drugs (Rischin et al, 2006; Overgaard, 2011).
CONSIDERATIONS
The ‘ideal’ PET tracer for tumour hypoxia. Table 3 presents a
summary of clinical imaging findings with the hypoxia tracers
discussed in this review. None of the currently available tracers
have all the properties that constitute the ideal PET hypoxia
tracer, and therefore none is optimal for imaging hypoxia in all
Table 3. Matrix summarising clinical imaging findings with leading hypoxia tracers
Tumour type 18F-FMISO 18F-HX4 18F-FAZA 18F-FETNIM 18F-EF5 18F-FRP170 Cu-ATSM
Brain Yes Not recommended Yes Recommended Yes Recommended
Head & Neck Yes Yes Yes Yes Yes Yes
Breast Yes
Sarcoma Variable data
Lung Yes Yes Yes Yes Yes Yes
Lymphoma Yes
Renal Variable data
Not recommended
Not recommended Not recommended Not recommended Not recommended Recommended
Liver Not recommended Recommended Not recommended Not recommended Not recommended
Colorectal Not recommended Yes Not recommended Not recommended Yes
Bladder Not recommended Not recommended Not recommended Not recommended Not recommended Recommended
Cervical Yes Yes Yes
Prostate No Not recommended
Note: Yes¼good clinical data obtained. No¼poor clinical data obtained. Not recommended¼preclinical/metabolic data unfavourable. Recommended¼preclinical/metabolic data
favourable.
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cancer types. Nevertheless, the feasibility of imaging hypoxia with
PET has been clinically demonstrated in various tumour entities
using several of the existing radiotracers. Much of the radiotracer
selection stems from the availability of the tracer, ease of synthesis,
and the tumour type.
The magnitude of the challenge of PET hypoxia imaging. A
challenging aspect of PET hypoxia imaging is the fact that hypoxic
tumours are often hypoperfused. Limited perfusion will restrict
effective delivery of tracer into the tissue often, influencing tracer
accumulation in regions of normal or tumour tissue, and often
yielding results that are complex to interpret. Several studies have
compared tumour perfusion with dynamic PET to ascertain
whether tracer accumulation reflects blood flow during imaging.
18F-FMISO (Bruehlmeier et al, 2004), 18F-FETNIM (Lehtio¨ et al,
2001), and 18F-FAZA (Shi et al, 2010) exhibited similar distribu-
tion patterns to [15O]-H2O PET (reflecting blood flow) up to
15min p.i., while different patterns were observed at later imaging
times, consistent with tracer accumulation in hypoxic regions.
Pharmacokinetic analysis of 18F-FMISO data suggests that
different hypoxia-perfusion profiles can be identified in tumours
(Thorwarth et al, 2005); the latter perhaps corresponding with the
heterogeneity observed in tumour hypoxia distribution patterns
(Grosu et al, 2007). The significant heterogeneity of the tumour
microenvironment in terms of perfusion and hypoxia necessitates
further clinical studies, not only to evaluate hypoxia-perfusion
patterns, but also their relationship to clinical outcome.
Validation of PET hypoxia measurements. Validation of PET
tracers as indicators of regional hypoxia is extremely challenging
and attempts to correlate PET images with other accepted hypoxia
markers have produced mixed and contradictory results. While
oxygen electrodes are considered to be the gold standard against
which PET hypoxia measurements are authenticated, comparisons
may yield several discrepancies due to the sampling limitations of
oxygen probes and the fact that it measures hypoxia in a different
location (interstitial for oxygen probes vs intracellular for PET), as
well as the fact that this technique will fail to distinguish between
necrotic and viable hypoxic tissue (Ho¨ckel et al, 1993). This may
partly explain results from several studies that have reported mixed
correlations between tracer uptake and oxygen electrode measure-
ments in various tumour types (Bentzen et al, 2003; Gagel et al,
2004, 2007; Zimny et al, 2006; Mortensen et al, 2010). Indirect
immunohistochemical methods based on the detection of exogen-
ous (e.g., pimonidazole and EF5) or endogenous hypoxia markers
(e.g., CAIX and HIF-1) have also been employed (Dehdashti et al,
2003a, b; Jubb et al, 2010), albeit with limited success. This is
primarily due to the fact that comparisons as such rely on
reproducible staining, and several representative biopsies (which
are not always available), and may often require a technically
challenging spatial co-registration between PET images with
immunohistochemistry photographs for analogies to be drawn.
Of note is the fact that although tracer accumulation has been
widely compared with pimonidazole staining preclinically (Dubois
et al, 2004), equivalent clinical comparisons have not yet been
performed. The differential detection of acute and chronic hypoxia
and the discrepancy between hypoxia at the microscopic level and
the macroscopic resolution of the PET voxel are factors that will
also limit the accuracy of such comparisons (Mortensen et al,
2010).
Reproducibility of PET hypoxia measurements. Validation of
the reproducibility of PET hypoxia measurements is also
particularly important for clinical applications. There are limited
clinical data available on scan reproducibility with PET hypoxia
biomarkers. Studies with 18F-FMISO in head-and-neck cancer
reported reproducible hypoxic volumes in PET scans performed
3 days apart, but a considerable degree of intratumoural spatial
variability in tracer accumulation (Nehmeh et al, 2008). Another
study with 18F-FMISO in lung cancer showed good inter-observer
reproducibility on the basis of visual analysis, but low inter-
observer agreement with respect to hypoxic volume measurements
(Thureau et al, 2013). A more recent 18F-FMISO study in head-
and-neck cancer reported high reproducibility in SUV and
tumour-to-reference tissue measurements in scans acquired 2 days
apart (Okamoto et al, 2013). Other than 18F-FMISO, a study with
18F-FETNIM in oesophageal cancer patients observed similar
uptake values between scans performed on separate days before
concurrent chemoradiotherapy, but a shift in the geographical
location of hypoxic regions (Yue et al, 2012). These heterogeneous
findings can be partly explained by the dynamic character of
hypoxia that will limit scan reproducibility. Although acute
hypoxia has been shown to minimally influence 18F-FMISO PET
imaging in simulations (Mo¨nnich et al, 2012), a study in head-and-
neck tumours that used sequential 18F-FMISO scans to distinguish
between regions of acute and chronic hypoxia, accounted for
14–52% of acute hypoxia (Wang et al, 2009); a percentage that is
comparable to the proportion of acute hypoxia measured in rodent
tumours. Methodological discrepancies (scan setup and image
acquisition protocol), the selection of hypoxic-to-normoxic thresh-
olds for the definition of hypoxic regions, the temporal variability
in intratumoural pO2 levels between consecutive measurements, as
well as the small number of patients in the majority of the studies
may also account for the observed disparities in reproducibility.
Further studies addressing the variability of PET hypoxia
measurements are warranted, so as to clarify uncertainties in
tumour hypoxia quantification.
CONCLUSIONS
As a number of PET hypoxia tracers have now been evaluated in
cancer patients, it is apparent that PET imaging can be a powerful
tool to identify hypoxia in the clinical setting. Although none of the
currently available tracers exhibit all of the properties of the ‘ideal’
hypoxia tracer or are optimal for imaging hypoxia in all tumour
types, studies have demonstrated the feasibility for imaging
hypoxia in various cancers. As the clinical utility and limitations
of PET hypoxia biomarkers are now being elucidated the process
will be facilitated by performing larger studies with these tracers
using standardised protocols and hypoxia definitions so as to
improve comparison between tracers in various tumour types.
This may be best achieved via inter-institutional collaborations that
should help to advance study designs and homogeneous data
reporting. Equally important are the performance of test–
retest studies, harmonisation of data reporting, and clinical
validation of hypoxia tracers. These key objectives must
be addressed before PET hypoxia tracers can be used to their full
clinical utility.
Search strategy and selection criteria. We searched PubMed and
Scopus using combinations of the following search terms: ‘tumor
hypoxia’, ‘oncology’, ‘PET’, ‘positron emission tomography’,
radiotherapy’, ‘nitroimidazoles’, ‘fluoromisonidazole’, ‘pimonida-
zole’, ‘FMISO’, ‘FAZA’, ‘FETNIM’, ‘FRP-170’, ‘HX4’, ‘Cu-ATSM’.
The search results were screened for relevance and the reference
lists of relevant publications were also surveyed. PubMed and
Scopus article recommendations were also examined for relevance.
Only papers published in English were considered. The final
reference list was compiled by considering papers published
between January 1973 and May 2014.
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